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Overline: Malaria 30 
One sentence Summary: Naturally acquired immune responses target infected red blood cell surface 31 
antigens of immature malaria transmission stages. 32 
33 
Abstract 34 
The recent decline in global malaria burden has stimulated efforts towards Plasmodium falciparum 35 
elimination. Understanding the biology of malaria transmission stages may provide opportunities to 36 
reduce or prevent onward transmission to mosquitoes. Immature P. falciparum transmission stages, 37 
termed stage I-IV gametocytes, sequester in human bone marrow before release into the circulation as 38 
mature stage V gametocytes. This process likely involves interactions between  host receptors and 39 
potentially immunogenic adhesins on the infected red blood cell (iRBC) surface. Here we developed a 40 
flow cytometry assay to examine immune recognition of live gametocytes of different developmental 41 
stages by naturally exposed Malawians. We identified strong antibody recognition of the earliest 42 
immature gametocyte-iRBCs (giRBCs) but not mature, stage V giRBCs. Candidate surface antigens 43 
(n=30), most of them shared between asexual- and gametocyte-iRBCs and others enriched in giRBCs, 44 
were identified by mass spectrometry and mouse immunizations, as well as correlations between 45 
responses by proteome microarray and flow cytometry. Naturally acquired responses to a subset of 46 
candidate antigens were associated with reduced asexual and gametocyte density, and plasma samples 47 
from malaria-infected individuals were able to induce immune clearance of giRBC in vitro. Infected RBC 48 
surface expression of 6 select candidate antigens was validated using specific antibodies in fluorescent 49 
microscopy and flow cytometry experiments, and genetic analysis revealed a subset with minimal 50 
variation across strains. Our data demonstrate that humoral immune responses to immature giRBCs and 51 
shared iRBC antigens are naturally acquired following malaria exposure. These humoral immune 52 
responses may have consequences for malaria transmission potential by clearing developing gametocytes, 53 
which could be leveraged for malaria intervention. 54 
 55 
 56 
 57 
 58 
  59 
Introduction 60 
Plasmodium falciparum malaria morbidity and mortality has decreased substantially in the last 61 
decade (1). These recent gains are threatened by the spread of artemisinin-resistant parasites (2) and 62 
insecticide-resistant mosquitoes (3). The recent achievements in malaria control and necessity to contain 63 
artemisinin resistance have stimulated malaria elimination initiatives that require a thorough 64 
understanding of the biology and epidemiology of malaria transmission and alternative transmission-65 
reducing interventions (4). 66 
P. falciparum transmission to mosquitoes is initiated when a small subset of asexually replicating 67 
blood stage parasites produce sexual progeny, or gametocytes. Gametocytes develop in human red blood 68 
cells (RBC) along 5 morphological transitions (Stage I-V); stage I-IV development takes place 69 
predominantly in the extravascular niche of the bone marrow and spleen (5-7). Mature Stage V 70 
gametocytes are released into the peripheral blood circulation where they may be ingested by a blood-71 
feeding mosquito upon which they egress from RBCs as activated gametes and fuse and form motile 72 
zygotes. Further sporogonic development renders the mosquito infectious to humans. Several sexual stage 73 
proteins have been identified that have no function in gametocyte development but are essential for 74 
gamete fertilization (e.g. Pfs48/45 and Pfs230) or post-fertilization development in the mosquito (e.g. 75 
Pfs25, Pfs28) (8).  76 
There is currently incomplete evidence for immune responses that affect gametocyte formation, 77 
maturation or circulation time (9). Several field studies suggested mature gametocyte clearance after 78 
repeated malaria exposure (10-13) and antibody responses against uncharacterized targets on mature 79 
gametocyte-infected red blood cells (giRBCs) have been associated with lower gametocyte densities (12, 80 
14). Another field study identified antibodies that bound the surface of stage II-V giRBCs and distorted 81 
early gametocyte morphology and maturation (15). Depending on which stage(s) they target, anti-82 
gametocyte immune responses could be involved in blocking extravascular adhesion of immature giRBCs 83 
and/or clearance of circulating mature giRBCs, in a manner similar to antibodies against the asexual 84 
antigen PfEMP1. PfEMP1 is an immunodominant antigen on the surface of RBCs infected with asexual 85 
parasites (aiRBC); anti-PfEMP1 antibodies have an established role in immune clearance by inhibiting 86 
vascular adhesion and by opsonizing aiRBCs for phagocytic clearance	(16, 17). aiRBC surface antigens 87 
other than PfEMP1 exist (18), and are associated with phagocytosis and cytotoxicity (19). The ligands 88 
involved in giRBC adherence may be different from those involved in endothelial binding of aiRBCs; 89 
giRBCs are localized to an extravascular compartment (5, 7), show limited binding to human endothelial 90 
cell lines and harbor minimal PfEMP1 on their surface (20). Whilst no specific giRBC ligand has been 91 
identified, one tenth of the early gametocyte proteome consists of putatively exported antigens called P. 92 
falciparum gametocyte-exported proteins (PfGEXPs) (21).  93 
Hypothesizing that developing gametocytes could be targets of antibody responses in the human host, 94 
we performed a systematic characterization of gametocyte stage-specific immune recognition and 95 
clearance. We demonstrate naturally acquired human immune responses targeting immature (stage I-III) 96 
but not more mature stage V giRBCs. Experiments using whole cells and surface-intact and surface-97 
depleted membrane fractions of diverse parasite strains provide evidence for giRBC surface antigens, 98 
most of them shared with aiRBCs. We further demonstrate that natural immunity to shared iRBCs 99 
correlates with reduced asexual and gametocyte burden and that a subset of the target antigens shows 100 
minimal sequence diversity.  101 
 102 
Results 103 
Human immune responses recognize secreted gametocyte proteins 104 
We first probed a Plasmodium falciparum peptide array enriched for proteins expressed in the gametocyte 105 
and gamete stages (22) with human plasma samples from 579 asymptomatically infected individuals from 106 
Cameroon, Burkina Faso, and the Gambia (22)(table S1) to examine natural immunity. Proteins were 107 
clustered based on their stage-specific abundance in blood and mosquito stages in proteomics studies (21, 108 
23, 24) and by cellular localization; localization was divided into those proteins that are parasite internal 109 
(internal/unknown localization) or secreted onto the merozoite or gamete surface or into the host cell in 110 
intra-erythrocytic stages (secreted)(fig. 1A-B, see also table S2). Five stage-specific clusters (gametocyte 111 
specific or shared with asexual stages) were enriched in secreted antigens (Figure 1A), and secreted 112 
antigens showed higher antibody responses compared to internal antigens for shared, gametocyte-specific 113 
(p-value = 8.86 x 10-288) and gametocyte/mosquito stage proteins (p-value = 4.31 x 10-119)(fig. 1C). 114 
Responses to shared secreted proteins increased with age while responses to secreted gametocyte or 115 
mosquito stage proteins or to parasite internal proteins did not. Correlations were highly significant for a 116 
total of 121 individual peptides (adjusted p-value < 0.05, table S3). Although responses to numerous 117 
protein fragments showed progressive increases with age (fig. S1A), responses to other antigens, 118 
including PTP6 (25) and GEXP08, reached a plateau in the 12-30 year old group (fig. S1B). These results 119 
indicate that humoral responses to secreted parasite antigens (shared and gametocyte-specific) are 120 
correlated with cumulative exposure to malaria.  121 
 122 
Immune responses target the immature but not the mature giRBC surface  123 
Detection of immune responses against secreted gametocyte proteins prompted us to directly examine 124 
immune recognition of giRBC surface antigens among an independent population. In a cross-sectional 125 
study, we collected plasma samples from 244 individuals with suspected malaria from southern Malawi 126 
(see Materials and Methods and table 1). A subset of rapid diagnostic test (RDT)+ samples and an RDT- 127 
control (representative of the entire Malawian study population in terms of age and sex distribution) was 128 
incubated with P. falciparum NF54 stage II/III giRBC, stage V giRBCs, or activated gametes. Surface 129 
reactivity was measured by comparing the percentage of IgG-positive cells between incubations with 130 
Malawian and naïve control sera (see fig. S2 and S3). To differentiate non-activated gametocytes (i.e., 131 
intact giRBCs) from activated ones (i.e., free gametes), stage V incubations were co-stained with 132 
antibodies recognizing the gametocyte/gamete surface antigen Pfs48/45 (which becomes accessible upon 133 
RBC rupture and giRBC activation) and the RBC surface antigen Glycophorin C. Highest surface 134 
reactivity was found for gametes (mean 25.80% recognized cells), with substantial reactivity also 135 
observed for stage II/III (mean 6.22%) but not for stage V giRBCs (fig. 2A). The relatively low 136 
percentage of giRBCs recognized suggests low abundance, accessibility and/or immunogenicity of 137 
putative antigen targets. Of the Malawian plasma samples tested, 75.00% (n/N=18/24) and 95.83% 138 
(n/N=23/24) recognized stage II/III giRBCs or gametes respectively, whereas no samples were positive 139 
for stage V recognition (fig. 2B).  140 
 We further investigated antibody specificity to immature giRBC surface antigens as compared to 141 
aiRBCs using a transgenic version of the Ghanaian P. falciparum parasite Pf2004 (26, 27), 142 
Pf2004_164/TdTom. This parasite expresses the TdTomato reporter under the control of the PF10_0164 143 
promoter (28) that allows detection by fluorescence microscopy and flow cytometry of gametocytes of all 144 
stages except the first 30 hours of development (fig. 2C). Among 244 Malawian plasma samples, the 145 
strongest responses to aiRBCs correlated with the strongest responses to giRBCs, whereas 14 samples 146 
were uniquely positive for giRBCs (fig. 2D-E). No differences between RDT+ and RDT- individuals in 147 
antibody responses for any antigen class was observed (fig. S4A). When we repeated our surface 148 
recognition experiments with the 3D7 reference strain (a clone of NF54 used in fig. 2A, potentially 149 
expressing different surface proteins than Pf2004), we observed lower surface antigen expression and 150 
lower non-specific IgG labeling from naïve serum compared to Pf2004 (fig. S4B-C). These strain 151 
disparities are consistent with previous work observing differential reactivity of Kenyan plasma samples 152 
to parasite strains of different genetic origins (18). Surface protein removal with trypsin/chymotrypsin 153 
revealed that both specific and non-specific binding of IgG involved antigens on the surface of aiRBCs 154 
and giRBCs (fig. S4D-E). Further experiments using the same patient sera and naïve controls revealed no 155 
IgM binding above background and therefore excluded IgM binding as an explanation for the observed 156 
non-specific surface recognition (fig. S5). These data provide strong evidence for IgG-targeted antigens 157 
that are shared between asexual and gametocyte stages. 158 
 The prevalence (number of samples with substantial aiRBC and/or giRBC recognition) and 159 
magnitude (median fluorescence intensity) of iRBC reactivity was significantly higher for adults 160 
compared to children (fig. 2F). The increased aiRBC reactivity with age (top panel) corroborates the well-161 
characterized pattern of increasing breadth of antibody response to asexual parasites with cumulative 162 
exposure (29-31). The slower age-dependent increase for giRBC responses (bottom panel) may reflect the 163 
lower abundance of immature gametocytes and suggests that giRBC responses differ from those against 164 
gametocyte/gamete antigens Pfs48/45 and Pfs230 that appear short-lived	(22, 32, 33). We then probed a 165 
subset of the Malawian plasma samples (representing a range of reactivity by flow cytometry) on the 166 
peptide array to identify recognized targets. Recognition of the giRBC surface by flow cytometry was 167 
correlated with mean array responses for shared asexual-gametocyte and gametocyte-specific secreted 168 
antigens (fig. 2G) but not internal proteins. Individuals recognizing giRBCs by flow cytometry had 169 
significantly higher reactivity (p-value <0.05) to a subset of 22 protein fragments (including 4 shared and 170 
13 gametocyte-specific) compared to individuals with minimal reactivity to giRBCs (table S4 and fig. 171 
S1C). Altogether these data demonstrate that plasma samples recognizing both aiRBCs and giRBCs show 172 
the highest magnitude in reactivity, and this signal is driven by antibody responses against secreted 173 
antigens across all age groups. 174 
 175 
Antigens on the giRBC surface are predominantly shared with aiRBC  176 
TdTomato fluorescence increases with later stage gametocytes (Figure 3A) and microscopy and flow 177 
experiments indicated that “weak TdTomato+” corresponded to stage I/II gametocytes and “strong 178 
TdTomato+” to stage II/III gametocytes. Three lines of evidence suggest that giRBC surface reactivity is 179 
specific for stage I/II gametocytes: i) a higher percentage of stage I/II, weak TdTomato signal consistently 180 
corresponded to a higher percentage of cells staining positive for the surface (Figure 3B); ii) the intensity 181 
of IgG staining correlated with the percentage of weak TdTomato positive cells (Figure 3C); iii) 182 
microscopy confirmed significantly higher percentages of surface labeling of aiRBCs and stage I/II 183 
giRBCs compared to stage II/III giRBCs (Figure 3D). These results demonstrate that giRBC reactivity is 184 
highest in early stage gametocytes (stage I/II) and decreases during gametocyte development. 185 
To identify the target giRBC surface antigens, we probed aiRBC and stage I-III giRBC membranes 186 
+/- treatment with trypsin/chymotrypsin (hereafter referred to as +trypsin and –trypsin samples) with 187 
Malawian plasma samples by Western blot. By comparing differential bands between surface-intact (-188 
trypsin) and surface-depleted (+trypsin) samples, we identified both shared (aiRBC-giRBC) and giRBC-189 
specific trypsin-sensitive protein bands (Figure 4A), demonstrating the presence of immunogenic 190 
antigens on the giRBC surface. Next, we performed mass spectrometry-based proteomics of stage I-III 191 
giRBC membrane samples and assessed reactivity of sera from mice immunized with the same giRBC 192 
membrane samples. These results were combined with the proteins recognized by individuals with giRBC 193 
reactivity by flow cytometry in experiments described above to form an initial list of potential giRBC 194 
surface antigens.  195 
In the first approach, we performed whole lane in-gel digestion with 3 biological replicates of 196 
+trypsin vs. –trypsin giRBC membranes and identified differentially enriched protein bands between the 197 
two conditions by mass spectrometry (fig 4B; table S5). Overall, 72.20% of proteins identified in –198 
trypsin samples were shared between all 3 replicates and 92.21% of proteins were identified 199 
unequivocally in at least 2 of the 3 replicates. Out of all 235 proteins that were >1.25x enriched in the –200 
trypsin sample (table S5), a subset of 30 (12.77%) secreted proteins were considered putative surface 201 
antigen candidates. Secreted proteins were defined by the presence of at least one transmembrane domain 202 
(TM, including the N-terminal signal sequence) and either known localization to membrane/surface or 203 
host cell or unknown localization. Within this set of 30 candidates, 28 (93.33%; 11.91% of total candidate 204 
list) showed evidence for export into the host cell based on predicted PEXEL motif (21 proteins) or 205 
PEXEL/HT negative exported protein (PNEP) annotation (7 proteins) and 23 were expressed in both 206 
asexual and gametocyte stages. Importantly, this candidate list includes several previously identified 207 
secreted antigens such as multiple Plasmodium helical interspersed subtelomeric (PHIST) family proteins 208 
(21, 34, 35), PIESP2 (35-37), and GEXP02 (21, 38).   209 
In a complementary antigen-discovery approach, we immunized mice with the same surface-intact (-210 
trypsin) or surface-depleted (+trypsin) giRBC membranes used for proteomics and probed sera on our 211 
gametocyte-enriched protein array. Several bands on Western blot were present only in experiments using 212 
sera from mice immunized with surface-intact giRBC membranes, and were reduced in intensity when 213 
surface-depleted membranes were probed with these sera compared to surface-intact membranes (fig. 214 
4C). Sera from all mice showed similar responses to parasite-internal peptides on the array, but sera from 215 
mice immunized with –trypsin preparations showed significantly higher responses to secreted proteins 216 
compared to mice immunized with +trypsin preparations (p-value=0.04315)(fig. 4D). Due to lower 217 
background using mouse sera compared to human sera, many normalized mean response values were 218 
negative; however, the significant differential responses were consistent with observed reduced band 219 
intensity after trypsin treatment by Western blot (fig. 4C) and with the same array probed with human 220 
plasma samples described earlier. Consistent with our previous results using the peptide array, 16 221 
individual protein fragments elicited significantly higher differential responses with sera from mice 222 
immunized with surface-intact membranes (fig. 4E, table S6). Notably, GEXP07 and GEXP10, two 223 
proteins on the iRBC surface that can bind to the chemokine CX3CL1 (37) were recognized both by sera 224 
from mice immunized with intact and surface-depleted membranes (fig. 4F), suggesting that their 225 
ectodomain is trypsin insensitive.  226 
In total, we identified an overlapping set of 68 initial candidate giRBC surface antigens: 22 proteins 227 
with significantly correlated array vs. flow cytometry responses (table S4), 30 proteins from mass 228 
spectrometry-based proteomics (table S5), and 16 proteins eliciting significantly higher responses from 229 
sera from mice immunized with surface-intact (compared to surface-depleted) giRBC membranes (table 230 
S6). This list was then filtered based on detection by gametocyte surface proteomics and presence of at 231 
least one TM; subsequently any proteins with confirmed localization within the parasite or 232 
parasitophorous vacuole or Maurer’s clefts were removed. The remaining 30 proteins were therefore 233 
deemed potential giRBC surface antigens (table S7): 26 were identified by surface proteomics, 3 by the 234 
parallel mouse immune profiling experiment and 1 hit was identified only by correlating protein array 235 
responses and surface reactivity of patient plasma samples. Of the 30 candidate antigens, 26 (86.7%) 236 
showed evidence of export into the host cell based on the presence of a PEXEL (23 proteins) or PNEP (3 237 
proteins) motif, and the majority of the identified proteins (23: 76.7%) were expressed both in asexual and 238 
gametocyte stages (i.e., shared expression profile). Importantly, there is independent evidence for 239 
localization at the iRBC periphery and/or surface for 12 out of these 30 candidates from previous studies 240 
(Supplementary table S7), further supporting our data. 241 
 242 
Validation of giRBC antigen surface localization 243 
From the 30 proteins, we selected 9 for experimental validation of surface expression using antibodies 244 
against peptides (PF3D7_0402000, PF3D7_0702500, PF3D7_0936800, PTP5, PTP6, GEXP02 and 245 
GEXP10; GEXP07 and GEXP10 (37)), or recombinant protein (PF3D7_0532400 (39)) (table S8) in 246 
Western blots (fig. 5A), flow cytometry (fig. 5B), and live immunofluorescence assays (fig. 5B-C). In 247 
addition, we performed IFAs using fixed, permeabilized cells to determine the cellular distribution of the 248 
candidate proteins (fig. 5D). We obtained a band of the expected size by Western blot, and candidate 249 
antigens showed variable degrees of trypsin sensitivity (fig. 5A and fig. S6). All antibodies except PTP6, 250 
which did not detect giRBCs, were then tested by flow cytometry (fig. 5B) and immunofluorescence 251 
microscopy (fig. 5B-C) using live Pf2004/164TdTomato parasites. By flow cytometry, all antibodies, 252 
except those against GEXP10 and GEXP07, showed significantly reduced recognition of surface-depleted 253 
asexual stages and early gametocytes although cell binding was low for some antibodies (fig. 5B, right 254 
panel). The overall percentage of cells labeled, as well as the magnitude of decreased labeling after 255 
trypsin treatment, were higher by live IFA fig. 5B, left panel; fig. 5C) compared to flow cytometry. 256 
Again, GEXP10 and GEXP07 appeared insensitive to trypsin treatment in these assays. Apart from 257 
trypsin sensitivity we quantified the proportion of surface-labeled aiRBCs and giRBCs, the fluorescence 258 
intensity of surface labeling, and the average percentage of surface coverage among labeled cells by live 259 
microscopy (fig. 5C, left panel). Whereas GEXP10 and GEXP07 showed high levels for all 3 260 
measurements, other antibodies had high values for one or two parameters (fig. 5C). Automatic 261 
independent clustering by all 3 measurements simultaneously confirmed 6 candidates - PTP5, GEXP02, 262 
PF3D7_0936800, GEXP07, GEXP10 and PF3D7_0702500. In contrast, the two candidates with major 263 
expression in asexual stages and minimal expression in gametocytes based on our proteomic clustering 264 
(PF3D7_0402000, PF3D7_0532400) showed the lowest levels of giRBC surface staining by live 265 
microscopy. Finally, immunofluorescence microscopy using fixed and permeabilized cells confirmed 266 
significant labeling at the iRBC periphery, and in addition, co-labeling with the Maurer’s Cleft marker 267 
SBP1, for 3 of these candidates across asexual and immature gametocyte stages (fig. 5D). Antibodies 268 
against all three candidates showed markedly weaker labeling in gametocytes compared to asexual 269 
parasites. Altogether, analysis of a subset of candidates using peptide antibodies validated our analysis 270 
pipeline and confirmed six proteins as giRBC surface antigens.  271 
 272 
A subset of secreted parasite antigens shows minimal sequence diversity and elicits responses that are 273 
correlated with reduced gametocyte burden 274 
To determine the extent of sequence polymorphisms amongst the antigens analyzed in this study, we 275 
measured signatures of selection in the encoding genes from clinical isolates collected from two patient 276 
populations in Senegal and Malawi (table S9). Analysis of nonsynonymous pairwise nucleotide diversity 277 
(πNS) demonstrated significantly elevated levels of genetic diversity in genes encoding secreted compared 278 
to internal antigens across all stages (fig. 6A and S7A; Mann-Whitney U test, p = 8x10-13 (Senegal), p = 279 
3.7x10-11 (Malawi)). Genes with Tajima’s D values above the genome-wide 95th percentile (D>-0.343), 280 
indicating balancing selection, were also enriched in secreted relative to internal antigens (fig. S7B; 281 
Fisher’s Exact Test, p=0.0153 (Senegal), p=0.00660 (Malawi)). These data support the hypothesis that 282 
acquired immunity drives genetic diversity in genes encoding secreted P. falciparum blood stage antigens 283 
(both shared and gametocyte-specific). Indeed, we measured a positive correlation between immune 284 
responses against secreted antigens and the levels of πNS of the encoding genes (Pearson’s correlation; 285 
r=0.221, p=0.000141 (Senegal); r=0.199, p=0.000623 (Malawi)). Levels of πNS were significantly 286 
increased at mean responses greater than 0.5 across secreted antigens, suggesting a threshold effect 287 
inducing positive selection through antibody-mediated immunity (fig. 6A; Mann-Whitney U test, 288 
p=0.0265 (Senegal), p=0.0441 (Malawi)). We also quantified genetic differentiation between the two 289 
geographically separated parasite populations in Malawi and Senegal using the fixation index (FST). This 290 
analysis demonstrated that genes encoding secreted antigens show significantly higher FST indices (Mann-291 
Whitney U test, p=2.3x10-5), and that the majority of genes had high corresponding indices (FST > 292 
0.1)(fig. 6B; Mann-Whitney U test, p=2.3x10-5). Amongst our 30 candidate antigens, 9 showed minimal 293 
levels of nucleotide diversity across parasite populations in Malawi and Senegal (fig. S7C, and table S9). 294 
Seven antigens, including the validated surface antigens GEXP07 and PTP5, show both minimal levels of 295 
nucleotide diversity across parasite populations and low levels of population divergence between 296 
populations (fig. S7C, and table S9). Altogether, genetic analysis demonstrates that genes encoding 297 
secreted antigens show significantly higher signatures of selection compared to internal antigens whilst a 298 
subset of eight antigens show minimal levels of genetic diversity and may thus elicit strain-transcending 299 
immunity (table 2).  300 
 It is currently unknown whether antibodies recognizing shared or gametocyte-specific surface 301 
antigens may inhibit giRBC binding/sequestration and/or increase phagocytosis efficiency by 302 
opsonization - as implicated in responses to PfEMP1 (18, 40, 41) and merozoite antigens (42, 43). To 303 
directly test this hypothesis, we opsonized iRBCs with the same Malawian plasma samples used for iRBC 304 
surface labeling and determined the level of iRBC phagocytosis by THP-1 cells	(18). Significant levels of 305 
iRBC phagocytosis were detected (fig. 6C), and the magnitude of surface reactivity was significantly 306 
correlated with induction of phagocytosis both for aiRBCs and giRBCs (fig. 6D). Altogether these data 307 
demonstrate existence of functional antibodies targeting both aiRBCs and giRBCs, and provide evidence 308 
for antibody-mediated clearance of giRBCs. In support of these functional assays, the intensity of 309 
recognition of shared secreted antigens by plasma samples from individuals in Cameroon, Burkina Faso, 310 
or the Gambia was overall negatively associated with the gametocyte fraction in these individuals 311 
(quantified by coefficients of regressing antigen response on logit-transformed gametocyte fraction). In 312 
contrast, normalized recognition of asexual antigens was overall negatively associated with asexual stage 313 
and gametocyte load (also quantified by regression coefficients, antigen response on log-transformed 314 
asexual/gametocyte load), whereas normalized recognition of gametocyte-specific antigens did not show 315 
any negative association (fig. 6E). Furthermore, the proportion of total parasites that were gametocytes 316 
was negatively associated with breadth of response to the 76 fragments representing the 31 candidate 317 
surface antigens on the peptide array (coefficient, -0.002 (95% CI -0.004/-0.0004), p=0.019). Importantly, 318 
responses to a total of 12 candidate surface antigens, including three of our final candidates (Table 2) 319 
showed significant (p<0.05) negative correlation between immune response and both peripheral 320 
gametocyte and asexual stage load (fig. 6F and S8, and table S10). These data support the phagocytosis 321 
data and suggest that iRBC immunity may be able to simultaneously reduce total parasite burden and 322 
gametocyte burden.  323 
 324 
Discussion 325 
In this study, we systematically addressed immune recognition of antigens on the surface of giRBCs and 326 
provide evidence for the identity of these proteins. Our combination of a flow cytometry assay using 327 
distinct gametocyte stages, immune profiling by protein microarray, 3 parallel methods of antigen 328 
discovery, and a functional assay to quantify antibody-mediated iRBC phagocytosis, provides evidence 329 
for naturally acquired antibodies recognizing shared asexual/gametocyte and gametocyte-specific 330 
antigens on the surface of immature giRBCs.  331 
Two previous studies reported immune recognition of mature giRBCs (12, 14) but did not  332 
specifically control for gametocyte activation. We regularly observed glycophorin-negative gametocyte 333 
populations where the giRBC membrane was lost due to activation or permeabilization. It is conceivable 334 
that earlier studies have similarly experienced a loss in RBC integrity and may thus have detected 335 
antibodies against gamete proteins, that are common in endemic populations (22), instead of mature 336 
giRBC responses. Less stringent methods of giRBC purification also could have hindered detection of 337 
responses targeting the most immature stages. When we carefully prevented activation by using a 338 
compound that prevents gamete egress (44), and confirmed the intact RBC membrane by counterstains 339 
(the gamete surface antigen Pfs48/45 and the RBC surface antigen Glycophorin C), we did not detect 340 
significant recognition of stage V giRBC. In addition, we observed strong reactivity to stage I/II 341 
gametocytes but negligible reactivity to stage V gametocytes in our highly synchronous TdTomato 342 
transgenic parasite line (45). Our data demonstrate that plasma from naturally exposed individuals 343 
strongly recognizes early stage I/II giRBCs and aiRBCs; the majority of immunogenic giRBC antigens in 344 
our study are also expressed in asexual stage parasites. These observations have potential implications for 345 
our understanding of parasite biology. Asexual and early gametocyte stages of P. falciparum, P. vivax, 346 
and P. berghei are abundantly present in the bone marrow parenchyma	(5, 7, 46, 47), suggesting 347 
environmental characteristics supporting both gametocyte development and a genuine asexual replication 348 
cycle. An independent study recently confirmed that both bone marrow and spleen represent major 349 
reservoirs for parasite development in rodent malaria	(48). We hypothesize that shared antigens present 350 
on aiRBC and giRBC surfaces are involved in cellular interactions in the bone marrow parenchyma and 351 
critical for the maturation of both asexual and gametocyte stages. In such a model, the aiRBC surface 352 
serves the dual purpose of vascular adherence and extravascular binding, while the giRBC surface is 353 
optimized for extravascular binding only. Indeed, recent work demonstrated trypsin-sensitive binding of 354 
aiRBCs and immature but not mature giRBCs to human bone marrow mesenchymal stromal cells (49). 355 
Interestingly, two antigens we identified on the giRBC and aiRBC surface, GEXP07 and GEXP10, were 356 
recently described as aiRBC surface proteins that bind the chemokine CX3CL1 (37). As expression of 357 
this chemokine on bone marrow stromal cells is involved in homing and retention of monocytes (50), it is 358 
tempting to speculate that GEXP07 and GEXP10 are involved in such interactions between iRBCs and 359 
other cell types. It remains to be determined why human IgG levels recognizing giRBC antigens are 360 
generally lower compared to aiRBCs and why recognition is restricted to young gametocyte stages, 361 
despite their continued presence in the extravascular niche until maturity. Although we only examined 362 
stage I/II, III and V gametocytes, and not the intermediate stage IV, our data suggest reduced antigen 363 
expression on the giRBC surface over the course of gametocyte development, the mechanism of which 364 
could include a combination of membrane remodeling, protease activity, or release via extracellular 365 
vesicles. As the molecular mechanisms of the bone marrow sequestration process become further 366 
elucidated, the ability and function of natural antibodies to access this compartment in meaningful 367 
concentrations and effectively target parasites in this niche is likely to also be revealed.  368 
Our data reveal a positive correlation between antibody-mediated immunity and genetic diversity in 369 
secreted parasite antigens. Nevertheless, we identified a small set of immunogenic candidate antigens 370 
with minimal genetic diversity within and between populations, suggesting that they may induce strain-371 
transcendent immunity. Our plasma samples were from cross-sectional surveys in asymptomatic 372 
populations. Whilst this makes it unlikely that inflammation or acute disease have influenced the results, 373 
our sampling approach means we were lacking details on gametocyte commitment and maturation, and 374 
were thus unable to test causality between antibody responses and parasite and gametocyte dynamics. We 375 
observed that the proportion of the total parasite biomass that is gametocyte (indicating what fraction of 376 
parasites successfully develops into circulating mature gametocytes	(51)) was reduced in infections of 377 
individuals who responded to peptides mapping to shared asexual/gametocyte antigens. The negative 378 
associations between responses to asexual secreted antigens and asexual parasite load suggest a specific 379 
role for these proteins in reducing asexual parasite burden, in addition to the established contribution of 380 
anti-PfEMP1 antibodies (18, 19). Importantly a total of 12 candidate antigens, including 3 of our 8 top 381 
candidates with low sequence diversity, showed negative correlations between antibody titer and both 382 
asexual and gametocyte load, suggesting an association with reduced parasite growth and gametocyte 383 
maturation or clearance. This possible phenotype of the detected antibody responses is supported by our 384 
finding that plasma samples with increased aiRBC and giRBC surface recognition demonstrate increased 385 
phagocytosis of aiRBC and giRBC by THP-1 cells. This phenotype and the identification of a small set of 386 
target immunogenic antigens present on the giRBC surface with low sequence diversity, provides a 387 
rationale for a novel transmission blocking vaccine strategy that may interfere with gametocyte 388 
maturation. Such a vaccine approach would reduce the number of gametocytes in the circulation and 389 
hence transmission potential.   390 
Altogether, we provide compelling evidence for natural immune responses targeting young 391 
gametocytes and their antibody-mediated immune clearance. We identify a small set of 8 candidate 392 
antigens that are i) expressed in gametocytes (7 of them are also expressed in asexual stages), ii) elicit 393 
natural antibody responses and iii) display low sequence diversity.  394 
 395 
Materials and Methods 396 
Study design 397 
For the Malawi study, samples were collected over 4 weeks in July/August 2013. Two weeks were spent 398 
in Chikhwawa, as this region had higher malaria transmission during this time of year and one week each 399 
in Ndirande and Thyolo. All individuals receiving an RDT at the clinic were referred to our study and 400 
samples were taken from all of those individuals who consented to the study. The end of data collection 401 
was not determined by any factor other than the end of the defined sample collection period. Samples 402 
from two individuals who withdrew their consent after participation were discarded; all other samples 403 
were shipped to the US for further experiments. We aimed to detect natural antibody responses among the 404 
study participants that recognize giRBCs and then to determine the targets of these antibody responses. 405 
To examine antibody binding to the giRBC surface, we used a surface reactivity flow cytometry assay, 406 
immunofluorescence microscopy and a protein array enriched for proteins expressed during gametocyte 407 
stages. In these experiments, samples were identified only by number and patient age and corresponding 408 
clinical data was unblinded only after experiments finished. Three technical replicates were used for all 409 
samples and two biological replicates were performed for a subset of samples. In cases where the result 410 
from one technical replicate was of a different magnitude than the other 2 replicates, this value was 411 
removed. To determine the identity of antigens targeted by the identified antibodies, we used mass 412 
spectrometry and immunization of mice with giRBC membranes, each using 3 biological replicates for 413 
preparation of giRBC membranes. Surface expression of candidate antigens was validated by Western 414 
blot, flow cytometry, and immunofluorescence microscopy. Functional activity was assessed using a 415 
THP-1 cell phagocytosis assay. Sequence diversity was assessed using standard methods 416 
(nonsynonymous pairwise nucleotide diversity, balancing selection measured by Tajima’s D, genetic 417 
differentiation measured by the fixation index).  418 
 419 
Statistical analysis 420 
The appropriate statistical test for each experiment was determined based on the type of data being 421 
compared. FDR corrections were performed for all analyses involving multiple comparisons and p-values 422 
<0.05 were considered significant. Simple univariate linear regressions were performed for examining the 423 
correlation between levels of IgG responses against individual fragments on the protein array and 424 
covariates including (ordinally categorized) age, burden, and iRBC recognition by flow cytometry. P-425 
values across fragments were corrected with Bonferroni method. Pairwise, two-sided student t-tests were 426 
used to test for difference in mean IgG response against proteins across stages. Linear regressions were 427 
used to test for associations between IgG response against fragments and parasite load, gametocyte load 428 
and gametocyte fraction, with adjustment for age by including age groups as covariates. The regression t-429 
statistics (estimated coefficients / standard error) of internal and secreted protein fragments are compared 430 
by two-sided Mann-Whitney U test. The association of gametocyte fraction and breadth of response 431 
(number of proteins seropositive) was conducted on gametocyte positive individuals for whom asexual 432 
and gametocyte stages had been quantified. Analysis on breadth and fraction on continuous scales was 433 
performed with linear regression, adjusting for gametocyte density. Analysis with breadth as a binary 434 
variable was performed with logistic regression, adjusting for gametocyte density. Throughout the 435 
manuscript significant p-values are reported either as is or with the corresponding alpha-level (all < 0.05). 436 
 437 
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Figures legends 783 
 784 
Figure 1: Human plasma samples recognize secreted asexual (aiRBC) and gametocyte (giRBC) 785 
surface antigens. 786 
A. Heat map of 344 P. falciparum antigens from 3D7 genome (PlasmoDB Release 31) clustering proteins 787 
on the array by timing of protein expression (log read counts of number of peptides sequences). 788 
Additional annotations are indicated by color bars at the top of the heat map: first row indicates cluster 789 
stage annotation from (52) (orange: gametocyte rings, red: immature gametocytes, blue: mature 790 
gametocytes, grey: others), and second row indicates cellular localization (black: secreted, white: 791 
internal/unknown). Vertical red lines separate stage-specific clusters. Black boxes highlight 5 clusters of 792 
shared or gametocyte-specific secreted antigens. B. Distribution of 528 P. falciparum protein fragments 793 
on the peptide array (developed in (22)) by stage and location. The proteins were selected based on 794 
expression during gametocyte stages and predicted export (details in table S2). C. Mean responses across 795 
3 malaria-exposed populations are quantified by peptide array (after normalization to controls and 796 
quantile normalization), stage of protein expression, and whether they are secreted or not (see table S1). 797 
GAM=Gametocyte, GAM/MO=Gametocyte/Mosquito stages, MO=Mosquito stages, A=Asexual stages, 798 
SA=Shared antigens. 799 
  800 
 801 
Figure 2: Immune responses target the immature but not the mature giRBC surface.  802 
A-B. Results from a pilot flow cytometry study testing reactivity of 24 Malawian plasma samples (22 803 
from Chikhwawa, a high transmission region, and 2 from Ndirande, a low transmission region) and 5 804 
naïve controls against stage II/III and stage V gametocytes and gametes. Positive surface reactivity (> 3 805 
standard deviations above mean of naive controls) is shown both as percentage of significantly positive 806 
samples of all those tested (A) and percentage of positive cells among those incubated with an individual 807 
plasma sample (B). C. Schematic for gating strategy of giRBC surface detection in 244 Malawian plasma 808 
samples by flow cytometry. IgG positivity is determined using the Pf2004_164/TdTom line that allows 809 
selection of the parasite population (positive for DNA dye) and TdTomato (positive for gametocytes). 810 
Top panel: Cells are first gated for live cells and single cells by forward and side scatter (left). After 811 
debris is gated out, quadrant gates separate gametocytes (Violet+/TdTomato+), asexual/lysed cells/debris 812 
(Violet+/TdTomato-), and uninfected cells (right). Bottom panel: AlexaFluor488 surface fluorescence 813 
(human IgG-secondary antibody conjugates) is compared between uninfected cells and gametocytes (left), 814 
and between infected cells incubated with naïve controls and Malawian plasma samples (right). Technical 815 
replicates are shown as individual lines. D-E. Positive recognition of aiRBCs and stage II/III giRBCs 816 
(determined by t-tests comparing Malawi samples to naïve US controls using the Holm-Sidak method 817 
with alpha=0.05) by 244 Malawian plasma samples is shown as prevalence (D) and as significant fold 818 
change in AlexaFluor488 median fluorescence compared to naïve controls (E). The threshold for specific 819 
positive reactivity was set to 1.1 based on the highest level of non-specific reactivity (i.e. reactivity to 820 
aiRBCs of human plasma significantly positive for stage II/III giRBC but negative for aiRBC). F. 821 
Correlation of human plasma recognizing aiRBCs (top panel) and giRBCs (bottom panel) by flow 822 
cytometry with age. G. Correlation of antigen responses by peptide array vs. surface recognition by flow 823 
cytometry. For the same set of Malawi plasma samples, normalized peptide array signal intensities were 824 
averaged across all shared stage antigens (top panel) or gametocyte-specific antigens (bottom panel). 825 
These mean responses were correlated with giRBC recognition by flow cytometry as measured by median 826 
fluorescence (AlexaFluor488) fold change compared to naïve controls. Overall, mean responses of shared 827 
secreted antigens are significantly correlated with giRBC recognition (p=0.004), whereas the other 828 
correlations are non-significant. Significance values: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 829 
0.0001. 830 
  831 
 832 
Figure 3: Human IgG selectively recognizes the early (stage I/II) giRBC surface.  833 
A. Stage-specific expression of the TdTomato reporter in transgenic Pf2004/164TdTom parasites by flow 834 
cytometry. Reporter expression is shown by fluorescence intensity in a time course across stage I-III 835 
gametocytes. B. The Violet+TdTomato+ gametocyte population detected by flow cytometry can be 836 
separated into weak TdTomato+ (stage I/II gametocytes) and strong TdTomato+ (stage II/III) subgroups. 837 
C. Correlation between TdTom signal and human IgG based on flow cytometry data (Pearson’s 838 
correlation, p<0.0001). D. Fluorescence microscopy analysis using the same antibody and reporter 839 
combination as above. Left panel: Surface labeling is present on both asexual parasites (arrows) and early 840 
gametocytes (arrowheads). Right panels: High content image quantification of fluorescence microscopy 841 
data, based on proportion of the cell surface that is labeled (top panel) and stratified by intensity (bottom 842 
panel).  843 
  844 
 845 
Figure 4: Immunogenic gametocyte antigens identified by 3 complementary approaches. A. Surface-846 
depleted vs. surface-intact uninfected and infected RBC membranes were probed with Malawian plasma 847 
samples and naïve US sera by Western blot. Each lane represents protein extract from 2.5×106 uRBC or 848 
iRBC. Differential band patterns between the trypsin(+) and trypsin(-) samples are marked with red 849 
arrows. B. Volcano plot showing human and Plasmodium proteins identified by comparing surface-intact 850 
vs. surface-depleted giRBC membranes. X-axis represents log2 fold change of -trypsin/+trypsin and Y-851 
axis shows the T-test p-value (p<0.05 corresponds to p-value 0.0004 after Benjamin-Hochberg 852 
correction) of -trypsin/+ trypsin biological replicates (n=3). Plasmodium proteins with a log2 fold change 853 
>1.25 are marked in red and significant Plasmodium proteins across 3 replicates are marked in blue. C. 854 
Surface-depleted (+trypsin/chymotrypsin) vs. surface intact (-trypsin/chymotrypsin) uRBC and giRBC 855 
membranes were probed with sera from mice (6 per group) immunized with surface-intact or surface-856 
depleted giRBCs by Western blot. Each lane represents protein extract from 2.5×106 uRBC or iRBC. 857 
Differential band patterns between the trypsin(+) and trypsin(-) giRBC samples are shown in red. D. The 858 
array described in Figure 1 was probed with sera from mice immunized with either surface-depleted or 859 
surface-intact giRBC membranes. Responses were normalized to controls and then quantile normalized. 860 
E. PTP6 and GEXP21 differential responses between sera from mice immunized with surface-intact (-861 
trypsin) giRBC membranes and surface-depleted (+trypsin) giRBC membranes. F. GEXP07 and GEXP10 862 
differential responses from sera from mice immunized with intact and surface-depleted membranes. See 863 
table S7 for complete data set.  864 
  865 
 866 
Figure 5: Six candidate antigens expressed during gametocyte stages are validated on the giRBC 867 
surface.  868 
Previously published GEXP07 and GEXP10 antibodies (37) target the putative extracellular loops of 869 
these proteins and will be referred to as “GEXP07 EL” and “GEXP10 EL” to distinguish from our newly 870 
produced peptide antibodies targeting the same proteins. A. MACS purified aiRBC or giRBC membranes 871 
(+/- pre-treatment with trypsin/chymotrypsin: hereafter referred to as +/- trypsin) are probed with 872 
polyclonal antibodies targeting candidate antigens by Western blot (see full blots in Supplemental 873 
Figure S6). Antibodies against Glycophorin C (trypsin-sensitive, surface expressed) and β-spectrin 874 
(trypsin resistant, internally localized) are included as controls. Each lane represents protein extract from 875 
2.5×106 iRBC. B. Reactivity of candidate antibodies to surface of MACS-purified Pf2004/164TdTomato 876 
iRBCs (+/- trypsin/chymotrypsin) was detected by live microscopy (left panel) and flow cytometry (right 877 
panel), using the same sample preparations in parallel. For live microscopy, the percentage of surface 878 
labeled aiRBCs or stage I giRBCs (weak TdTomato+) are shown for all antibodies tested. No asexual 879 
samples were tested for GEXP02 and PF3D7_0402000. For flow cytometry, cells were gated for live 880 
cells, single cells, and then uRBCs and giRBCs were gated based on Vybrant Violet and TdTomato 881 
fluorescence and surface reactivity measured using AlexaFluor488-conjugated secondary antibody . The 882 
TdTomato positive population was further split into “weak TdTomato+” (corresponding to earlier 883 
gametocytes) and “strong TdTomato+” (corresponding to later gametocytes) populations. C. Antibodies 884 
were clustered (automatic independent clustering) based on the imaging parameters shown in the 885 
heatmap: percentage of labeled giRBCs, average MFI at the giRBC cell surface, % giRBC surface 886 
covered, and ratio of MFI at the surface of –trypsin samples compared to +trypsin. Glycophorin C is 887 
included as a control. Live representative images of early giRBCs +/-trypsin treatment are shown for 888 
GEXP07 and GEXP10. D. Immunofluorescence analysis of the localization of GEXP02, GEXP10, and 889 
PF3D7_0936800 (detected with anti-peptide antibodies) in fixed, permeabilized aiRBCs and giRBCs 890 
(days 2 and 4 of the induction, corresponding to stages I-IIA and IIA-IIB, respectively). Candidate protein 891 
is shown in green, SBP1 in magenta, TdTomato in red, and nuclear staining in blue. 892 
 893 
 894 
  895 
 896 
Figure 6: Candidate gametocyte surface antigens elicit responses correlated with reduced 897 
gametocyte burden and a subset show minimal genetic diversity.  898 
A. Nonsynonymous nucleotide diversity for all antigens present on the protein array, stratified by stage, 899 
localization and level of immune response (Mann-Whitney U Test, p < 0.05). Genome data are from a set 900 
of parasite samples in Senegal. B. Population differentiation between Senegal and Malawi parasite 901 
samples for secreted and internal proteins (FST at nonsynonymous sites; Mann-Whitney U Test, p = 2.0 902 
x10-5). The dotted and dashed lines mark the 99th and 95th percentile of genome-wide nonsynonymous FST 903 
values. C. Left panel: internalized aiRBCs and giRBCs upon phagocytosis by THP-1 cells. aiRBCs are 904 
stained with the nuclear dye dihydroethidium (DHE) and giRBCs show TdTomato (TdTom) reporter 905 
fluorescence. Right panel: phagocytosis index of Malawi plasma samples relative to positive control 906 
(rabbit anti-human RBC) and naive US serum. D. iRBC phagocytosis vs. surface recognition. E. 907 
Associations were estimated between gametocyte fraction (gametocytes/total parasites), gametocyte and 908 
asexual parasite load, and secreted antigen fragment responses by peptide array (after normalization to 909 
IVTT controls and quantile normalization as in Figure 1) across 3 malaria-exposed populations. Median 910 
standardized regression coefficient -0.86, Wilcoxon test p=0.087. F. Regression coefficients (and 95% 911 
confidence intervals) between individual protein fragments of the prioritized candidate antigens and 912 
parasite parameters (either gametocyte fraction, gametocyte load or asexual parasite load). Fragments are 913 
stratified by their correlation with parasite parameters.  Significance values: *, p < 0.05; **, p < 0.01; ***, 914 
p < 0.001; ****, p < 0.0001. 915 
 916 
  917 
Tables: 918 
Age (years) Gender Location RDT status 
≤5 106 
(43.44%) 
Male 102 (41.8%) Chikhwawa 171 (70.1%) + 169 (69.3%) 
>5,≤12 28 (11.48%) Female 142 (58.2%) Ndirande 35 (14.3%) - 75 (30.7%) 
>12,<30  47 (19.26%)   Thyolo 38 (15.6%)   
≥30 63 (25.82%)       
Total       244 	919 
Table 1. Characteristics of Malawian study population. Chikhwawa has year-round malaria 920 
transmission whereas Ndirande and Thyolo have more seasonal transmission peaking during the rainy 921 
season each year. RDT=rapid diagnostic test. 922 
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 925 
Accession ID Export motif 
Protein 
description 
Stage 
annotation  
Previously 
described 
localizations 
Detection 
method 
Host 
phenotypes Conservation 
Validated 
surface 
expression 
PF3D7_0601900 PNEP 
Conserved 
Plasmodium 
protein, 
unknown 
function 
 
Shared Maurer’s clefts Proteomics  Pf  
PF3D7_0713700 NO 
Conserved 
Plasmodium 
protein, 
unknown 
function 
 
Gam/Mo Unknown Proteomics 
Neg correlation 
with asex./gam. 
load 
Pf, Pv, Pb  
PF3D7_0721100 PEXEL 
Conserved 
Plasmodium 
protein, 
unknown 
function 
 
Shared RBC surface  
Proteomics
Array/flow 
correlation 
pos. correlation 
with age/neg. 
correlation with 
asex./gam. load 
Pf, Pv, Pb  
PF3D7_0812100 NO 
Conserved 
Plasmodium 
protein, 
unknown 
function 
 
Shared Unknown Proteomics 
pos. correlation 
with age/neg 
correlation with 
asex./gam. load 
Pf, Pv, Pb  
PF3D7_0831400 PEXEL 
Plasmodium 
exported 
protein, 
unknown 
function 
(Hyp12) 
 
Shared Unknown Proteomics  Pf   
PF3D7_1002100 PEXEL 
EMP1-
trafficking 
protein 
(PTP5) 
 
Shared Maurer’s clefts Proteomics  Pf X 
PF3D7_1038000 NO 
Antigen 
UB05 
 
Shared Unknown Proteomics  Pf, Pv, Pb  
PF3D7_1301700 PEXEL 
Plasmodium 
exported 
protein 
(hyp8), 
unknown 
function 
(GEXP07) 
 
Shared RBC surface 
Proteomics/ 
Mouse sera 
array 
(+trypsin 
enriched) 
 Pf X 
	926 
Table 2: Prioritized candidate gametocyte antigens. 8 candidate gametocyte antigens were identified by: 927 
1) predicted or known host secretion, 2) proteomics of trypsin-treated and –untreated giRBC membranes, 3) 928 
correlations between plasma reactivity by protein array and flow cytometry, 4) array reactivity of serum from 929 
mice immunized with trypsin-treated and –untreated giRBC membranes, 5) exposure-dependent increase of 930 
IgG in malaria-positive individuals, 6), negative correlation with asexual and gametocyte load, and 7) low 931 
genetic diversity and divergence. 3 candidates (marked in bold) fulfill all criteria (1-6). Previously described 932 
stage annotation and localization was retrieved from plasmodb.org (21, 23, 24, 53). Further details on 933 
candidates are provided in table S7 and for 3 top candidates in fig. S8. Pf=P. falciparum; Pv=P. vivax, 934 
Pb=P. berghei.	935 
 936 	937 
 938 
